← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 201개
ADCBiologicstaleNektar TherapeuticsPhase 2

NKTR-255 (NKTR-255)

Multiple Myeloma; Non-Hodgkin Lymphoma · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 4상태 RECRUITING
CGTBiologicstaleElvira UmyarovaPhase 1

Universal Donor Expanded TGF-beta-imprinted NK Cells (Universal Donor Expanded TGF-beta-imprinted NK Cells)

Recurrent Multiple Myeloma; Refractory Multiple Myeloma · HER2

#HER2#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 4상태 ACTIVE
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, 89Zr-daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
임상시험 3상태 ACTIVE
CGTBiologicJuno Therapeutics, Inc., a Bris…Phase 2

Arlocabtagene Autoleucel (Arlocabtagene Autoleucel)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 3상태 RECRUITING
CGTBiologicstaleCARsgen Therapeutics Co., Ltd.Phase 2

CAR-BCMA T Cells (CAR-BCMA T Cells)

Refractory or Relapsed Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 3상태 ACTIVE
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 3상태 RECRUITING
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Selinexor, dexamethasone, ixazomib, pomalidomide (Selinexor, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 ACTIVE
ADCBiologicstaleMultiple Myeloma Research Conso…Phase 2

Venetoclax, dexamethasone, ixazomib, pomalidomide (Venetoclax, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 ACTIVE
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, 89Zr-DFO-daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
임상시험 2상태 DISCONTINUED
ADCBiologicstaleAbbViePhase 1

ABBV-838 (ABBV-838)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 2상태 DISCONTINUED
CGTBiologicstaleYake Biotechnology Ltd.Phase 2

BCMA CAR-T cells (BCMA CAR-T cells)

Multiple Myeloma; New Diagnosis Tumor · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 2상태 ACTIVE
CGTBiologicstaleBioray LaboratoriesPhase 2

BCMA-CART (BCMA-CART)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 2상태 DISCONTINUED
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab Mafodotin, Cyclophosphamide and Dexamethasone)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 3%임상시험 2상태 DISCONTINUED
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin frozen liquid)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 34%임상시험 2상태 ACTIVE
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin, Venetoclax)

Multiple Myeloma; Multiple Myeloma in Relapse · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 RECRUITING
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide)

Relapsed Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 2상태 ACTIVE
CGTBiologicstaleCartesian TherapeuticsPhase 2

Descartes-08 (Descartes-08)

Multiple Myeloma · Antisynthetase Syndrome

#AntisynthetaseSyndrome#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 2상태 RECRUITING
AntibodystalePfizerPhase 2

Elranatamab-bcmm (Elranatamab-bcmm)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
임상시험 2상태 RECRUITING
CGTBiologicstaleJuno Therapeutics, a Subsidiary…Phase 2

JCARH125 (JCARH125)

Non Hodgkin Lymphoma; Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 42.9%임상시험 2상태 ACTIVE
AntibodystaleTakedaPhase 2

Mezagitamab (Mezagitamab)

Relapsed and/or Refractory Multiple Myeloma (RRMM) · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 25%임상시험 2상태 ACTIVE

4 / 11 페이지

← 이전다음 →